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This report presents the case of a 36-year-old female who, at the
age of 16, presented at a gynecologic clinic with primary amenorrhea.
After thorough examination, the patient was diagnosed with AIS and
a 46,XY karyotype but either did not return to the clinic or was lost to
follow-up. Twenty years later, the same patient presented to our hospi-
talwith abdominal swelling and a large abdominalmass. The patientwas
156 cm in height, 76 kg in weight, and of a female external phenotype
with well-developed breasts (Tanner IV), a blind-ending vagina, and no
axillary or pubic hair. A tumor the size of 23 cm indiameterwas detectedIntroduction
Complete androgen insensitivity syndrome (AIS) is a rare X-linked
disease with an estimated prevalence of 1 in 20,000 and is characterized
by a 46,XY karyotype and a female external phenotype (Wisniewski et
al., 2000). AIS is caused by mutations in the androgen receptor gene,
located on chromosome Xq11-12, which results in impaired embryonic
sexual differentiation. The risk of malignancy is considerably lower in
complete AIS than in partial AIS or other intersex disorders and occurs
at a later age (Cheikhelard et al., 2008). Morris reported a 22%
incidence of malignant gonadal tumors in patients over 30 years of
age (Morris, 1953); however, because 50% of the patients studied
had already undergone a previous gonadectomy, the risk of malig-
nancy was underestimated. Current recommendations for patients
with AIS suggest that cryptorchid testes be retained through puber-
ty in order to receive the beneﬁts from their hormone production,
enhance bone maturation, and allow completion of secondary
sexual development (Alvarez et al., 2005). Currently, limited data
is available on individuals who have not had their testes removed
(Deans et al., 2012). We report a case of a seminoma that developed
in the testes 20 years after diagnosis of AIS.d Gynecology, Hyogo College of
, Japan. Fax: +81 798 46 4163.
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Inc.Open access under CC BY license.in the abdomen by palpation and was determined to be solid upon ex-
amination by computed tomography (CT) and magnetic resonance im-
aging (MRI) images (Fig. 1A). Results of laboratory tests showed
elevated serum levels of cancer antigen (CA)-125 (325 IU/mL), lactate
dehydrogenase (LD; 485 IU/mL), and beta-human chorionic gonadotro-
pin (beta-hCG; 8.5 ng/mL). Serum levels of alpha-fetoprotein, testoster-
one, free testosterone, estradiol, luteinizing hormone, and follicle-
stimulating hormone were 2.1 ng/mL, 3.9 ng/mL, 7.8 pg/mL, 33 pg/mL,
13.3 mIU/mL, and 10.6 mIU/mL, respectively. Abdominal biopsy of a
tumor on the left ovary showed that the tumor was a seminoma
(Fig. 2A). Because of the size of the tumor, 3 courses of neoadjuvant che-
motherapy (NAC) (BEP: bleomycin [20 mg/m2] on days 1, 8, and 15;
etoposide [100 mg/m2] on days 1–5; and cisplatin [20 mg/m2] on days
1–5, repeated every 3 weeks) were administered. Following NAC, the
tumor shrank to the size of 3.5 cm in diameter (Fig. 1B), and serum levels
of CA-125, LD, and beta-hCG decreased to within the normal levels.
Abdominal surgery was performed to remove the tumors derived from
the left and right gonads (Fig. 3), and pathological examination revealed
that no residual tumor remained in the obtained specimen (Fig. 2B). The
serum levels of testosterone, free testosterone, and estradiol were
maintained after NAC but declined to 0.25 ng/mL, 0.9 pg/mL, and
15 pg/mL, respectively, after the removal of the right and left gonads. Ge-
netic analysis determined that the patient had a de novo 2-base deletion
in the androgen receptor gene, which introduced a stop codon at posi-
tion 500 of exon 1. The patient was treatedwith estrogen and had no ev-
idence of recurrence in the 52 months following surgery.Discussion
Complete AIS is typically diagnosed at puberty after an individual pre-
sents with primary amenorrhea or an inguinal hernia. Several long-term
Fig. 1. Magnetic resonance imaging of a tumor developing from the left testis in a patient with androgen insensitivity syndrome. (A) Before chemotherapy, a T2-weighted image
showed that the internal intensity was slightly high. (B) Marked shrinkage of the tumor occurred after 3 cycles of neoadjuvant chemotherapy (NAC).
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ectomy can be delayed until completion of sexual maturation because
pubertywill cause the spontaneous conversion of testosterone to estradi-
ol (Cheikhelard et al., 2008; Chantilis et al., 1994). Although there are no
standard or reliable screening tools for early detection of malignant
changes in patients with AIS, routine ultrasound examination is usually
conducted. Once puberty is complete, prophylactic gonadectomy is
recommended (Purves et al., 2008), and continual estrogen replace-
ment is required for maintaining bone health and general good health.
For patients who exhibit malignant transformation, adjuvant ther-
apy must be considered. If the tumor is contained within the testis,
the standard adjuvant treatment is postoperative irradiation of the
paraaortic lymph nodes with or without irradiation of the ipsilateralA
Fig. 2. (A) A biopsy specimen obtained before chemotherapy showed evenly spaced and
(B and C) Inﬁltration of lymphocytes was noticed, but tumor cells were not seen after NApelvic lymph nodes. Because the present patient had such a large
tumor, primary en bloc resection was thought to be too harmful to
the surrounding organs (Rescorla et al., 2003). A pathologically com-
plete response was observed after 3 cycles of NAC with BEP.
Inmost cases, complete AIS is an X-linked recessive disease. However,
the present patient had a de novo mutation of the androgen receptor
gene; her mother was not a carrier of this mutation. When the patient
ﬁrst visited a clinic, she and her family did not receive adequate genetic
or psychological counseling. Neither close follow-up nor prophylactic go-
nadectomywas conducted, and the patient exhibitedmalignant transfor-
mation. Although the patient survived without recurrence at 52 months
after surgery, this case reafﬁrms the importance of appropriate genetic
counseling for patients with AIS (Purves et al., 2008).B
C
relatively large uniform tumor cells with distinct cell borders (magniﬁcation × 200).
C (B, magniﬁcation × 40; C, magniﬁcation × 200).
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Fig. 3. Laparotomy after NAC. (A) The tumor shrank following NAC. (B) The right testis is indicated by an asterisk. (C) The uterine streak is indicated by arrows.
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